Herriot Tabuteau combined his Yale medical degree and two decades in finance to start Axsome Therapeutics. Now the company has three drugs on the market and five more in the pipeline.
This Haiti-Born Doctor Built A $6 Billion Business Developing Drugs For Depression And Alzheimer’s
Herriot Tabuteau combined his Yale medical degree and two decades in finance to start Axsome Therapeutics. Now the company has three drugs on the market and five more in the pipeline.
www.forbes.com
October 1, 2025 at 10:40 AM
Herriot Tabuteau combined his Yale medical degree and two decades in finance to start Axsome Therapeutics. Now the company has three drugs on the market and five more in the pipeline.
Axsome is planning to file for approval of its Alzheimer's agitation drug. But experts say the drug doesn't actually work.
My latest for Being Patient with comment from @ewidera.bsky.social and @profrobhoward.bsky.social
www.beingpatient.com/axsome-agita...
My latest for Being Patient with comment from @ewidera.bsky.social and @profrobhoward.bsky.social
www.beingpatient.com/axsome-agita...
Axsome Asks FDA to Approve Questionable Alzheimer’s Agitation Drug
Axsome will file for FDA approval their Alzheimer's agitation drug later this year. Outside experts question the drug's efficacy.
www.beingpatient.com
January 20, 2025 at 3:50 PM
Axsome is planning to file for approval of its Alzheimer's agitation drug. But experts say the drug doesn't actually work.
My latest for Being Patient with comment from @ewidera.bsky.social and @profrobhoward.bsky.social
www.beingpatient.com/axsome-agita...
My latest for Being Patient with comment from @ewidera.bsky.social and @profrobhoward.bsky.social
www.beingpatient.com/axsome-agita...
here are the others:
Yes on 50 campaign (twice)
Vraylar anti depressant (Abbvie)
Auvelity anti depressant (Axsome Therapeutics)
The law offices of Larry H. Parker
Covered California
U.S. Air Force
Jacoby & Meyers
Sweet James accident attorneys (twice)
Yes on 50 campaign (twice)
Vraylar anti depressant (Abbvie)
Auvelity anti depressant (Axsome Therapeutics)
The law offices of Larry H. Parker
Covered California
U.S. Air Force
Jacoby & Meyers
Sweet James accident attorneys (twice)
September 19, 2025 at 6:34 PM
here are the others:
Yes on 50 campaign (twice)
Vraylar anti depressant (Abbvie)
Auvelity anti depressant (Axsome Therapeutics)
The law offices of Larry H. Parker
Covered California
U.S. Air Force
Jacoby & Meyers
Sweet James accident attorneys (twice)
Yes on 50 campaign (twice)
Vraylar anti depressant (Abbvie)
Auvelity anti depressant (Axsome Therapeutics)
The law offices of Larry H. Parker
Covered California
U.S. Air Force
Jacoby & Meyers
Sweet James accident attorneys (twice)
FDA Approves Axsome Therapeutics’ AXS-07 for Migraine Treatment
"Marketed as Symbravo, the company noted that it anticipates AXS-07 to be commercially available in the United States in approximately 4 months."
#MigraineChat
"Marketed as Symbravo, the company noted that it anticipates AXS-07 to be commercially available in the United States in approximately 4 months."
#MigraineChat
FDA Approves Axsome Therapeutics’ AXS-07 for Migraine Treatment
Findings from previous phase 3 trial showed that treatment with AXS-07 resulted in significant reductions in headache pain freedom, migraine symptoms, and rescue medication use.
www.neurologylive.com
January 30, 2025 at 9:48 PM
FDA Approves Axsome Therapeutics’ AXS-07 for Migraine Treatment
"Marketed as Symbravo, the company noted that it anticipates AXS-07 to be commercially available in the United States in approximately 4 months."
#MigraineChat
"Marketed as Symbravo, the company noted that it anticipates AXS-07 to be commercially available in the United States in approximately 4 months."
#MigraineChat
My latest @forbes.com feature profiles Herriot Tabuteau, a Haitian immigrant, Yale-educated doctor + longtime investor, who started Axsome to tackle brain disorders. Now $AXSM has 3 drugs on the mkt + 5 more in the pipeline: “We’re not a small co in terms of ambition.”
www.forbes.com/sites/amyfel...
www.forbes.com/sites/amyfel...
This Haiti-Born Doctor Built A $6 Billion Business Developing Drugs For Depression And Alzheimer’s
Herriot Tabuteau combined his Yale medical degree and two decades in finance to start Axsome Therapeutics. Now the company has three drugs on the market and five more in the pipeline.
www.forbes.com
October 1, 2025 at 1:59 PM
My latest @forbes.com feature profiles Herriot Tabuteau, a Haitian immigrant, Yale-educated doctor + longtime investor, who started Axsome to tackle brain disorders. Now $AXSM has 3 drugs on the mkt + 5 more in the pipeline: “We’re not a small co in terms of ambition.”
www.forbes.com/sites/amyfel...
www.forbes.com/sites/amyfel...
Axsome Therapeutics $AXSM: Truist Securities raised its price target from $200.00 to $285.00 and maintained its Buy rating.
https://fundspec.ai/s/AXSM/analysts
Daily bullish and bearish AI signals on every US stock.
https://fundspec.ai/s/AXSM/analysts
Daily bullish and bearish AI signals on every US stock.
September 23, 2026 at 4:15 PM
Axsome Therapeutics $AXSM: Truist Securities raised its price target from $200.00 to $285.00 and maintained its Buy rating.
https://fundspec.ai/s/AXSM/analysts
Daily bullish and bearish AI signals on every US stock.
https://fundspec.ai/s/AXSM/analysts
Daily bullish and bearish AI signals on every US stock.
General rule: if a Pharma company doesn't publish the full data, just press releases and abstracts, then even they don't believe the results... (more detailed thoughts here in an article by @spichaksimon.bsky.social). #Alzheimers
www.beingpatient.com/axsome-agita...
www.beingpatient.com/axsome-agita...
Axsome Asks FDA to Approve Questionable Alzheimer’s Agitation Drug
Axsome will file for FDA approval their Alzheimer's agitation drug later this year. Outside experts question the drug's efficacy.
www.beingpatient.com
January 25, 2025 at 6:38 PM
General rule: if a Pharma company doesn't publish the full data, just press releases and abstracts, then even they don't believe the results... (more detailed thoughts here in an article by @spichaksimon.bsky.social). #Alzheimers
www.beingpatient.com/axsome-agita...
www.beingpatient.com/axsome-agita...
AXSOME THERAPEUTICS SHARES GAIN 1.4% PREMARKET AFTER FDA GRANTS PRIORITY REVIEW FOR CO'S ALZHEIMER’S AGITATION DRUG
December 31, 2025 at 12:26 PM
AXSOME THERAPEUTICS SHARES GAIN 1.4% PREMARKET AFTER FDA GRANTS PRIORITY REVIEW FOR CO'S ALZHEIMER’S AGITATION DRUG
The first office of Axsome Therapeutics had three desks, no windows and so little natural light that the people who worked there started calling it the broom closet. It was in Rockefeller Center. The year was 2012, and Herriot Tabuteau had just walked away
www.billionaires.africa/2026/04/05/m...
www.billionaires.africa/2026/04/05/m...
Meet Dr. Herriot Tabuteau, Haiti's first billionaire
Dr. Herriot Tabuteau came to America from Haiti at age nine and built a $6 billion brain disorder company that nobody believed in.
www.billionaires.africa
April 8, 2026 at 4:56 AM
The first office of Axsome Therapeutics had three desks, no windows and so little natural light that the people who worked there started calling it the broom closet. It was in Rockefeller Center. The year was 2012, and Herriot Tabuteau had just walked away
www.billionaires.africa/2026/04/05/m...
www.billionaires.africa/2026/04/05/m...
Axsome reports mixed Phase 3 data for AXS-05 in Alzheimer’s-related agitation—one trial hit its endpoint, one didn’t. Despite this, the company plans to seek FDA approval in late 2025, citing success in three of four studies.
Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval
Axsome Therapeutics on Monday reported data for two Phase 3 studies in Alzheimer’s-related agitation, saying one trial succeeded while the other failed.
endpts.com
December 30, 2024 at 4:28 PM
Axsome reports mixed Phase 3 data for AXS-05 in Alzheimer’s-related agitation—one trial hit its endpoint, one didn’t. Despite this, the company plans to seek FDA approval in late 2025, citing success in three of four studies.
Have a few patients on it that have had good success where previous therapies haven't been effective.
Coverage can be a pain but Axsome has programs for that too.
Coverage can be a pain but Axsome has programs for that too.
January 17, 2025 at 9:26 PM
Have a few patients on it that have had good success where previous therapies haven't been effective.
Coverage can be a pain but Axsome has programs for that too.
Coverage can be a pain but Axsome has programs for that too.
Axsome Therapeutics: Fortifying Market Dominance Through Strategic Patent Portfolios and Franchise Resilience - AInvest: Axsome Therapeutics: Fortifying Market Dominance Through Strategic Patent Portfolios and Franchise Resilience AInvest
Axsome Therapeutics: Fortifying Market Dominance Through Strategic Patent Portfolios and Franchise Resilience - AInvest
Axsome Therapeutics: Fortifying Market Dominance Through Strategic Patent Portfolios and Franchise Resilience AInvest
news.google.com
September 2, 2025 at 5:55 AM
Axsome Therapeutics: Fortifying Market Dominance Through Strategic Patent Portfolios and Franchise Resilience - AInvest: Axsome Therapeutics: Fortifying Market Dominance Through Strategic Patent Portfolios and Franchise Resilience AInvest
NEWS: ( NASDAQ: #AXSM ) Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
#StockMarket #News
#StockMarket #News
September 4, 2024 at 5:25 PM
SK바이오팜이 개발한 수면장애 치료제 ‘솔리암페톨(미국 제품명 수노시)’가 미국에서 성인 ADHD 환자 임상3상을 통과중이라고.
www.docdocdoc.co.kr/news/article...
특히 기존 약물의 두통,불면증 등 부작용이 없었다고. 노르에피네프린-도파민 재흡수 저해제 (NDRI), 당초 항우울제로 개발.
다만 약 판권은 이미 해외로 갔고, 한국 약값이 싼편이라 발매는 꽤 시간이 걸릴 것이라는 모양.
www.docdocdoc.co.kr/news/article...
특히 기존 약물의 두통,불면증 등 부작용이 없었다고. 노르에피네프린-도파민 재흡수 저해제 (NDRI), 당초 항우울제로 개발.
다만 약 판권은 이미 해외로 갔고, 한국 약값이 싼편이라 발매는 꽤 시간이 걸릴 것이라는 모양.
SK바이오팜 기술이전 ‘솔리암페톨’ 성인 ADHD 3상 청신호
SK바이오팜이 개발한 수면장애 치료제 ‘솔리암페톨(미국 제품명 수노시)’이 미국 액섬 테라퓨틱스(Axsome Therapeutics) 주도로 진행된 성인 ADHD 환자 대상 3상 임상시험에서 유의미한 효과를 입증했다.액섬 테라퓨틱스는 주의력결핍과잉행동장애(ADHD) 치료를 위한 솔리암페톨 3상 임상시험 연구(FOCUS) 톱라인(Topline) 데이터를 공개...
www.docdocdoc.co.kr
June 9, 2025 at 8:51 PM
SK바이오팜이 개발한 수면장애 치료제 ‘솔리암페톨(미국 제품명 수노시)’가 미국에서 성인 ADHD 환자 임상3상을 통과중이라고.
www.docdocdoc.co.kr/news/article...
특히 기존 약물의 두통,불면증 등 부작용이 없었다고. 노르에피네프린-도파민 재흡수 저해제 (NDRI), 당초 항우울제로 개발.
다만 약 판권은 이미 해외로 갔고, 한국 약값이 싼편이라 발매는 꽤 시간이 걸릴 것이라는 모양.
www.docdocdoc.co.kr/news/article...
특히 기존 약물의 두통,불면증 등 부작용이 없었다고. 노르에피네프린-도파민 재흡수 저해제 (NDRI), 당초 항우울제로 개발.
다만 약 판권은 이미 해외로 갔고, 한국 약값이 싼편이라 발매는 꽤 시간이 걸릴 것이라는 모양.
Axsome Wins 17 Years of Market Exclusivity for SUNOSI in Patent Settlement with Hetero - Stock Titan: Axsome Wins 17 Years of Market Exclusivity for SUNOSI in Patent Settlement with Hetero Stock Titan
Axsome Wins 17 Years of Market Exclusivity for SUNOSI in Patent Settlement with Hetero - Stock Titan
Axsome Wins 17 Years of Market Exclusivity for SUNOSI in Patent Settlement with Hetero Stock Titan
news.google.com
May 27, 2025 at 11:05 AM
Axsome Wins 17 Years of Market Exclusivity for SUNOSI in Patent Settlement with Hetero - Stock Titan: Axsome Wins 17 Years of Market Exclusivity for SUNOSI in Patent Settlement with Hetero Stock Titan
JUST IN: ( NASDAQ: #AXSM ) Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript
#StockMarket #News
#StockMarket #News
November 12, 2024 at 8:50 PM
JUST IN: ( NASDAQ: #AXSM ) Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript
#StockMarket #News
#StockMarket #News
Axsome Q2 Revenue Rises 46% But Misses Estimates as Soaring Costs Widen Net Loss https://signalbloom.ai/news/AXSM/axsome-q2-revenue-rises-46-but-misses-estimates-as-soaring-costs-widen-net-loss $AXSM #Earnings via @signalbloom.ai
August 10, 2026 at 11:10 AM
Axsome Q2 Revenue Rises 46% But Misses Estimates as Soaring Costs Widen Net Loss https://signalbloom.ai/news/AXSM/axsome-q2-revenue-rises-46-but-misses-estimates-as-soaring-costs-widen-net-loss $AXSM #Earnings via @signalbloom.ai
Did you know that agitation impacts up to 76% of Alzheimer's patients, often leading to hospitalization? A groundbreaking new treatment offers hope without the risks tied to traditional antipsychotics. 🧠✨
FDA approves first non-antipsychotic drug for agitation in Alzheimer's - Sinaptica
A historic approval for millions of patients
The U.S. Food and Drug Administration (FDA) approved the drug Auvelity (dextromethorphan + bupropion) from Axsome T
sinapti.ca
May 1, 2026 at 3:13 PM
Did you know that agitation impacts up to 76% of Alzheimer's patients, often leading to hospitalization? A groundbreaking new treatment offers hope without the risks tied to traditional antipsychotics. 🧠✨
To the FDA, drugmaker Axsome had shown that their new drug was better—by proving that bupropion didn’t work. This should be earth-shattering news: the FDA accepted the evidence that one of the most popular antidepressants—a drug that six million Americans are taking—is no better than placebo.
April 21, 2026 at 12:59 PM
To the FDA, drugmaker Axsome had shown that their new drug was better—by proving that bupropion didn’t work. This should be earth-shattering news: the FDA accepted the evidence that one of the most popular antidepressants—a drug that six million Americans are taking—is no better than placebo.